What is TENX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TENX?

P/E (TTM) is n/a and 52-week range is $1.31 to $19.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TENX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TENX?

The company profile lists revenue (TTM) near $49K, net income (TTM) near $-499M, EPS (TTM) near $-1.47 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tenax Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Chapel Hill, North Carolina, US, 26.5M shares outstanding, ISIN US88032L6056 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Tenax Therapeutics Inc

$TENX

Health Care · Biotechnology

IR Run Scenarios

$1.87

+0.54%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company is headquartered in Chapel Hill, North Carolina and currently employs 14 full-time employees. The firm is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The firm's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The firm is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The firm has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Employees

Website

www.tenaxthera.com/

IPO

1993-10-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)